このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

臓がんにおけるPIKfyve誘導の脂質代謝を標的とする

Caleb Cheng ^1,2,3, Jing Hu ^1,4,5, Rahul Mannan ^1,4

¹Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
²Medical Scientist Training Program, University of Michigan, Ann Arbor, MI, USA.
³Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, USA.
⁴Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
⁵Department of Pathology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China.
⁶Department of Urology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
⁷CRUK Scotland Institute, Glasgow, UK.
⁸Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.
⁹Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.
¹⁰Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
¹¹State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Beijing, People's Republic of China.
¹²Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
¹³Agilent Technologies, Lexington, MA, USA.
¹⁴Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
¹⁵Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
¹⁶Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
¹⁷Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
¹⁸School of Cancer Sciences, University of Glasgow, Glasgow, UK.
¹⁹Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. qiaoy@med.umich.edu.
²⁰Department of Pathology, University of Michigan, Ann Arbor, MI, USA. qiaoy@med.umich.edu.
²¹Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. qiaoy@med.umich.edu.
²²Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA. clyssiot@umich.edu.
²³Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. clyssiot@umich.edu.
²⁴Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA. clyssiot@umich.edu.
²⁵Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. arul@med.umich.edu.
²⁶Department of Pathology, University of Michigan, Ann Arbor, MI, USA. arul@med.umich.edu.
²⁷Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. arul@med.umich.edu.
²⁸Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA. arul@med.umich.edu.
²⁹Department of Urology, University of Michigan, Ann Arbor, MI, USA. arul@med.umich.edu.

⁰Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.

Nature +

|

2025年4月24日

PubMedで要約を見る

まとめ

臓がん (PDAC) の標的は脂質代謝を阻害する. PIKfyveの抑制とKRAS- MAPKの治療を併用すると,合成的致死性を誘導して腫瘍を排除し,新しい治療戦略を提示します.

科学分野

腫瘍学
癌代謝
脂質生物学

背景

管性腺がん (PDAC) は,オートファジーのような規制解除された微小環境と代謝経路に依存しています.
癌の代謝をターゲットにすることは有望ですが効果的な薬の標的を特定することは依然として困難です
PIKfyveはリソソーム機能に不可欠な脂質キナーゼであり,PDACの進行に関与しています.

研究の目的

PIKfyveをPDACの標的となる脆弱性として特徴づける.
PDACにおけるPIKfyve抑制の代謝的影響を調査する.
PDACモデルにおけるPIKfyveとKRAS- MAPK経路の結合阻害の有効性を評価する.

主な方法

PDACの遺伝子組み換えマウスモデルを使用した.
PIKfyveの抑制効果を理解するために,包括的な代謝分析を行った.
臨床前モデルのPIKfyveとKRAS- MAPKの同時標的化の影響を評価した.

主要な成果

PIKfyveはPDACの進行に不可欠です.
PIKfyveの阻害は,KRAS- MAPKシグナル伝達を通して,デノボ脂質合成のアップレギュレーションを誘導する.
PIKfyveの抑制とKRAS- MAPKの標的化により,臨床前モデルの腫瘍負担は排除されました.

結論

PIKfyveは PDACで薬剤を投与する標的です.
PIKfyveの阻害によって脂質代謝を妨害すると,合成致死性が生じます.
PIKfyveとKRAS- MAPKを標的とした組み合わせ治療は,PDACに対する有望な治療戦略です.

関連する概念動画

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...